神经病理性疼痛的药物治疗进展

赵佳丽; 陈秋红; 李红娜; 曾莉莉; 叶永贤; 费燕

doi:10.3969/j.issn.1006-0111.2016.04.006

神经病理性疼痛的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2016.04.006

1.
解放军175医院药学科, 福建漳州 363000
2.
解放军175医院骨科, 福建漳州 363000

基金项目: 解放军第一七五医院青年苗圃基金课题（15Y008）

Progress on drug therapy of neuropathic pain

1.
Department of Pharmacy, No. 175 Hospital of PLA, Zhangzhou 363000, China
2.
Department of Orthopaedics, No. 175 Hospital of PLA, Zhangzhou 363000, China

摘要: 神经病理性疼痛（NPP）是由一系列感染和神经损伤事件引起的慢性疼痛，其发病率高、病因复杂，严重影响患者的生活质量。尽管临床试验逐渐增多，但NPP的治疗仍存在不足。合理使用不同作用机制和持续时间的药物，是当前治疗NPP的研究热点。针对近年来NPP的药物治疗进展做一总结，为该病的治疗提供依据。
- 神经病理性疼痛 /
- 药物治疗 /
- 联合用药 /
- 靶向治疗
Abstract: Neuropathic pain (NPP) is a chronic pain that caused by a series of infection and nerve damage events. It has high incidence, complex etiology and seriously affects patients' life quality. Although clinic trials gradually increased, the treatment of neuropathic pain is still insufficient. Recent research focuses on reasonably using drugs of different mechanisms and time of duration. The progress of NPP drugs was reviewed in this paper for providing basis for treatment of neuropathic pain.
- neuropathic pain /
- drug therapy /
- drug combination /
- targeting therapy

[1]	Attal N, Bouhassira D. Neuropathic pain:experimental advances and clinical applications[J]. Rev Neurol, 2004, 160(2):199-203.
[2]	Lema MJ, Foley KM, Hausheer FH. Types and epidemiology of cancer-related neuropathic pain:the intersection of cancer pain and neuropathic pain[J]. Oncologist, 2010, 15(Suppl2):3-8.
[3]	Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain:involvement of inflammatory immune cells, immune-like glial cells and cytokines[J]. J Neuroimmunol, 2010, 229(1-2):26-50.
[4]	Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes:mechanisms of action and place in therapy[J]. Drugs, 2000, 60(5):1029-1052.
[5]	Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain[J]. Curr Pain Headache Rep, 2009, 13(3):185-190.
[6]	Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics:a review[J]. J Clin Pharmacol, 2012, 52(1):6-17.
[7]	Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline, in postherpetic neuralgia:a randomized, double-blind, crossover trial[J]. Pain, 1992, 48(1):29-36.
[8]	Jefferies K. Treatment of neuropathic pain[J]. Semin Neurol, 2010, 30(4):425-432.
[9]	Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision[J]. Eur J Neurol, 2010, 17(9):1113-1188.
[10]	Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain[J]. Diabetes Metab Res Rev, 2009, 25(7):623-631.
[11]	Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain:systematic review of randomised trials[J]. BMC Neurol, 2008, 8:29.
[12]	Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain:consensus statement and guidelines from the Canadian Pain Society[J]. Pain Res Manag, 2007, 12(1):13-21.
[13]	Dooley DJ, Taylor CP, Donevan S, et al. Ca²⁺ channel α-2-δ ligands:novel modulators of neurotransmission[J]. Trends Pharmacol Sci, 2007, 28(2):75-82.
[14]	Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain:a randomized controlled trial from the Gabapentin Cancer Pain Study Group[J]. J Clin Oncol, 2004, 22(14):2909-2917.
[15]	Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuopathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trial of flexible-and fixed-dose regimens[J]. Pain, 2005, 115(3):254-263.
[16]	Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain:A double-blind, randomized controlled crossover trial[J]. Lancet, 2009, 374(9697):1252-1261.
[17]	Griggs RB, Bardo MT, Taylor BK. Gabapentin alleviates affective pain after traumatic nerve injury[J]. Neuroreport, 2015, 26(9):522-527.
[18]	Câmara CC, Araújo CV, de Sousa KKO, et al. Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats[J]. Neurosci Lett, 2015, 607:52-58.
[19]	Baillie JK, Power I. Morphine, gabapentin, or their combination for neuropathic pain[J]. N Engl J Med, 2005, 352(25):2650-2651.
[20]	García de Paredes ML, del Moral González F, Martínez del Prado P, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients results of oncology study[J]. Ann Oncol, 2011, 22(4):924-930.
[21]	Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy:a randomized, double-blind, controlled, trial. Pain, 1999, 83(1):85-90.
[22]	Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain:an overview and literature update[J]. Mayo Clin Proc,2010,85(3):S3-S14.
[23]	Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy[J]. Pain, 2001, 91(1-2):101-109.
[24]	Vadivelu N, Hines RL. Buprenorphine:a unique opioid with broad clinical applications[J]. J Opioid Manag, 2007, 3(1):49-58.
[25]	Vadivelu N, Hines RL. Management of chronic pain in the elderly:focus on transdermal buprenorphine[J]. Clin Interv Aging, 2008, 3(3):421-430.
[26]	Johnson RE, Fudala PJ, Payne R. Buprenorphine:considerations for pain management[J]. J Pain Symptom Manage, 2005, 29(3):297-326.
[27]	Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain[J]. J Pain, 2009, 10(2):113-130.
[28]	神经病理性疼痛诊疗专家组. 神经病理性疼痛诊疗专家共识[J]. 中国疼痛医学杂志,2013,19(12):705-710.
[29]	Müller-Schwefe G, Jaksch W, Morlion B, et al. Make a change:optimizing communication and pain management decisions[J]. Curr Med Res Opin, 2011, 27(2):481-488.

[1]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[2]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[3]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[4]	杨彬, 王作君, 陈菡, 张敬一. 基于DRGs的医院合理用药管理机制探索实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404030
[5]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
[6]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[7]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[8]	陈金涛, 乔子婴, 马明华, 张若曦, 王振伟, 年华. 基于网络药理学和分子对接技术研究金芪清疏颗粒治疗社区获得性肺炎的潜在机制 . 药学实践与服务, 2024, 42(11): 471-478. doi: 10.12206/j.issn.2097-2024.202312014
[9]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[10]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[11]	丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉. 消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
[12]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[13]	景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞. 黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
[14]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[15]	陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼. 通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
[16]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
[17]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[18]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[19]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
[20]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049

点击查看大图

计量

文章访问数: 3822
HTML全文浏览量: 453
PDF下载量: 852
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

神经病理性疼痛的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2016.04.006

Progress on drug therapy of neuropathic pain

计量

神经病理性疼痛的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2016.04.006

1. 解放军175医院药学科, 福建漳州 363000

2. 解放军175医院骨科, 福建漳州 363000

English Abstract

Progress on drug therapy of neuropathic pain

1. Department of Pharmacy, No. 175 Hospital of PLA, Zhangzhou 363000, China

2. Department of Orthopaedics, No. 175 Hospital of PLA, Zhangzhou 363000, China

全文HTML

目录

留言板

神经病理性疼痛的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2016.04.006

Progress on drug therapy of neuropathic pain

计量

出版历程

神经病理性疼痛的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2016.04.006

1. 解放军175医院药学科, 福建 漳州 363000 2. 解放军175医院骨科, 福建 漳州 363000

English Abstract

Progress on drug therapy of neuropathic pain

1. Department of Pharmacy, No. 175 Hospital of PLA, Zhangzhou 363000, China 2. Department of Orthopaedics, No. 175 Hospital of PLA, Zhangzhou 363000, China

全文HTML

目录

1. 解放军175医院药学科, 福建漳州 363000

2. 解放军175医院骨科, 福建漳州 363000

1. Department of Pharmacy, No. 175 Hospital of PLA, Zhangzhou 363000, China

2. Department of Orthopaedics, No. 175 Hospital of PLA, Zhangzhou 363000, China